Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

Combination heart failure therapies significantly lower systolic blood pressure by up to 9.2 mmHg in HFrEF patients and around 5 mmHg in HFmrEF/HFpEF, with manageable effects on kidney function and potassium levels.

• Why it matters: Understanding short-term impacts of these therapies helps clinicians balance benefits and risks, addressing concerns about hypotension, kidney dysfunction, and hyperkalemia that hinder comprehensive treatment.
• What they did: The study pooled data from 38,753 participants across nine trials, developing a prediction model to estimate effects of ARNI, sMRA, nsMRA, and SGLT2i on blood pressure, kidney function, and potassium over 2-12 weeks.
• The result: Findings enable personalized treatment planning by providing estimates of blood pressure reduction and kidney and potassium changes, supporting safer, more effective therapy combinations for diverse heart failure patients.